Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...8990919293949596979899...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Journal, IO Biomarker:  Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells. (Pubmed Central) -  Jan 16, 2020   
    The effectiveness of targeted PDT is, like PDT, dependent on the generation of singlet oxygen and thus the availability of intracellular oxygen. The results of this study suggest that canine non-B, non-T NK lymphocytes have a potential ADCC function and that combinational strategies of monoclonal antibodies with either cytokines, which activate NK cells in vivo, or adoptive transfer of NK cells may be a feasible method for amplifying the efficacy of immunotherapy against malignant cancers even with very low expression of target molecules in dogs.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial primary completion date:  PD 0332991 and Cetuximab in Patients With Incurable SCCHN (clinicaltrials.gov) -  Jan 13, 2020   
    P1/2,  N=93, Recruiting, 
    Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial primary completion date: Dec 2019 --> Jun 2020
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date:  Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis (clinicaltrials.gov) -  Jan 13, 2020   
    P2,  N=40, Recruiting, 
    Trial primary completion date: Dec 2019 --> Jun 2020 Trial completion date: Jan 2019 --> Jun 2021 | Trial primary completion date: Dec 2018 --> Jan 2021
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Afinitor (everolimus) / Novartis
    Retrospective data, Journal, Adverse events:  Targeted Tumour Therapy Induced Papulopustular Rash and Other Dermatologic Side Effects: A Retrospective Study. (Pubmed Central) -  Jan 11, 2020   
    With the increasing use of targeted therapies, dermatologists are now confronted with the extensive spectrum of skin toxicities. Therefore, it is critical for dermatologists to be aware of these toxicities so as to develop the best approach without discontinuation of cancer therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  P57-mediated autophagy promotes the efficacy of EGFR inhibitors in hepatocellular carcinoma. (Pubmed Central) -  Jan 10, 2020   
    Through activating the PI3K/AKT/mTOR signaling pathway, p57 can reverse Er/C-225-induced autophagy, and thereby increase the therapeutic efficiency of Er/C-225 treatment. Given these results, p57 upregulation may be applicable as a therapeutic strategy to improve EGFR-targeted therapy in HCC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Targeted Polymer-Based Probes for Fluorescence Guided Visualization and Potential Surgery of EGFR-Positive Head-and-Neck Tumors. (Pubmed Central) -  Jan 10, 2020   
    Cetuximab increased tumor accumulation after 15 min, whereas GE 11 needed at least 4 h. Interestingly, after 4 h, there were no significant differences in tumor targeting, indicating the potential of oligopeptide targeting for fluorescence-navigated surgery. In conclusion, fluorescent polymer probes targeted by oligopeptide GE-11 or whole antibody are excellent tools for surgical navigation during oncological surgery of head and neck squamous cell carcinoma, due to their relatively simple design, synthesis and cost, as well as optimal pharmacokinetics and accumulation in tumors.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, sEphB4-HSA / VasGene, National Cancer Institute
    Enrollment open, Combination therapy, Metastases:  sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC (clinicaltrials.gov) -  Jan 8, 2020   
    P1,  N=30, Recruiting, 
    In conclusion, fluorescent polymer probes targeted by oligopeptide GE-11 or whole antibody are excellent tools for surgical navigation during oncological surgery of head and neck squamous cell carcinoma, due to their relatively simple design, synthesis and cost, as well as optimal pharmacokinetics and accumulation in tumors. Not yet recruiting --> Recruiting
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Biomarker Directed Treatment in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jan 8, 2020   
    P2,  N=47, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=30 --> 47 | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Aug 2019 --> Dec 2020
  • ||||||||||  depatuxizumab (ABT-806) / AbbVie, Life Science Pharma, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, CAR T-Cell Therapy:  EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. (Pubmed Central) -  Jan 8, 2020   
    We designed a CAR using a mAb806-based binder, which recognizes tumor-specific untethered EGFR...Unlike the nonselective Erbitux-based CAR, EGFR806-CAR T cells did not target primary human fetal brain astrocytes expressing wild-type EGFR, but showed a similar level of activity compared to Erbitux-CAR when the tumor-specific EGFRvIII transcript variant was overexpressed in astrocytes...In a novel human induced pluripotent stem cell (iPSC)-derived teratoma xenograft model, EGFR806-CAR T cells infiltrated but were not activated in EGFR+ epidermal cell nests as assessed by Granzyme B expression. These results indicate that EGFR806-CAR T cells effectively and selectively target EGFR-expressing tumor cells.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Clinical Trial,Phase II, Journal, BRCA Biomarker:  Exome sequencing of 22 genes using tissue from patients with biliary tract cancer. (Pubmed Central) -  Jan 5, 2020   
    Our panel is clinically validated and suitable for a high volume of samples to detect mutations in patients with BTC. However, it is reasonable to assume that the clinical utility could be optimized in this patient group by extending the panel to include BTC specific mutations with potential therapeutic consequences such as IDH1/2, FGFR-fusions, ERBB3 and BRCA1/2.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
    Biomarker, Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker:  Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck. (Pubmed Central) -  Dec 28, 2019   
    Still, the first line 'golden standard' is the chemotherapy regimen (cisplatin, 5-fluorouracyl) combined with cetuximab...Very encouraging results have been shown in early phase studies evaluating the combination of immune-checkpoint inhibitors with tumor microenvironment immunosuppressive inhibitors. Undoubtedly, further research in the field of biomarkers for effective immunotherapy is needed in order to select a group of patients whose will benefit from this therapy, as the treatment is still ineffective in most patients.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Retrospective data, Journal:  Relationship between the CT features of colorectal cancer metastases calcification and tumor response to chemotherapy (Pubmed Central) -  Dec 27, 2019   
    In patients with advanced colorectal cancer metastases treated with cetuximab combined chemotherapy, rapid growth of calcification density and increased calcification number may be valuable imaging features of therapeutic efficacy. The maximal calcification density and morphology of calcification are not related to the therapeutic efficacy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  The day after De-ESCALaTE and RTOG 1016 trials results. (Pubmed Central) -  Dec 25, 2019   
    However, data on biomarkers for EGFR-directed mAbs combined with immunotherapy or anti-angiogenic agents remain limited. No abstract available
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, erlotinib / Generic mfg.
    Journal:  Combinations of Bevacizumab and Erlotinib show activity in colorectal cancer independent of RAS status. (Pubmed Central) -  Dec 24, 2019   
    These results should provide a molecular framework to better understand the increased activity of the bevacizumab-erlotinib combination, compared to bevacizumab alone, in the GERCOR DREAM phase III clinical trial. Differential activity of mAbs and TKIs targeting the same signaling pathway is likely applicable for other tumor types.